vs
AETHLON MEDICAL INC（AEMD）与ANGIODYNAMICS INC（ANGO）财务数据对比。点击上方公司名可切换其他公司
ANGIODYNAMICS INC的季度营收约是AETHLON MEDICAL INC的1324.7倍（$79.4M vs $60.0K）。ANGIODYNAMICS INC净利率更高（-8.0% vs -2926.4%，领先2918.4%）。ANGIODYNAMICS INC自由现金流更多（$4.2M vs $-2.0M）
AETHLON MEDICAL INC是一家临床阶段医疗科技企业，专注开发针对性治疗类医疗器械，核心产品血液净化器可从血液中去除有害病毒、肿瘤外泌体及其他病原体，业务聚焦传染病和肿瘤治疗赛道，主要市场覆盖北美地区。
AngioDynamics是一家全球医疗技术企业，专注于研发、生产及销售微创医疗设备，核心产品覆盖血管通路、外科消融、肿瘤治疗等领域，面向北美、欧洲、亚太地区的医院、门诊手术中心及各类医疗机构提供服务。
AEMD vs ANGO — 直观对比
营收规模更大
ANGO
是对方的1324.7倍
$60.0K
净利率更高
ANGO
高出2918.4%
-2926.4%
自由现金流更多
ANGO
多$6.3M
$-2.0M
损益表 — Q3 2025 vs Q2 2026
| 指标 | | |
|---|---|---|
| 营收 | $60.0K | $79.4M |
| 净利润 | $-1.8M | $-6.3M |
| 毛利率 | — | 56.4% |
| 营业利润率 | -3026.4% | -7.7% |
| 净利率 | -2926.4% | -8.0% |
| 营收同比 | — | 9.0% |
| 净利润同比 | 49.4% | 40.9% |
| 每股收益（稀释后） | $-10.05 | $-0.15 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AEMDANGO
| Q4 25 | — | $79.4M | ||
| Q3 25 | — | $75.7M | ||
| Q2 25 | — | $80.2M | ||
| Q1 25 | — | $72.0M | ||
| Q4 24 | $60.0K | $72.8M | ||
| Q3 24 | $95.1K | $67.5M | ||
| Q2 24 | — | $71.0M | ||
| Q1 24 | — | $75.2M |
净利润AEMDANGO
| Q4 25 | — | $-6.3M | ||
| Q3 25 | — | $-10.9M | ||
| Q2 25 | — | $-6.0M | ||
| Q1 25 | — | $-4.4M | ||
| Q4 24 | $-1.8M | $-10.7M | ||
| Q3 24 | $-2.8M | $-12.8M | ||
| Q2 24 | — | $-13.4M | ||
| Q1 24 | — | $-187.7M |
毛利率AEMDANGO
| Q4 25 | — | 56.4% | ||
| Q3 25 | — | 55.3% | ||
| Q2 25 | — | 52.7% | ||
| Q1 25 | — | 54.0% | ||
| Q4 24 | — | 54.8% | ||
| Q3 24 | — | 54.4% | ||
| Q2 24 | — | 54.3% | ||
| Q1 24 | — | 47.7% |
营业利润率AEMDANGO
| Q4 25 | — | -7.7% | ||
| Q3 25 | — | -14.1% | ||
| Q2 25 | — | -7.2% | ||
| Q1 25 | — | -13.9% | ||
| Q4 24 | -3026.4% | -15.2% | ||
| Q3 24 | -3050.2% | -19.4% | ||
| Q2 24 | — | -20.4% | ||
| Q1 24 | — | -265.9% |
净利率AEMDANGO
| Q4 25 | — | -8.0% | ||
| Q3 25 | — | -14.4% | ||
| Q2 25 | — | -7.5% | ||
| Q1 25 | — | -6.1% | ||
| Q4 24 | -2926.4% | -14.7% | ||
| Q3 24 | -2950.2% | -19.0% | ||
| Q2 24 | — | -18.9% | ||
| Q1 24 | — | -249.7% |
每股收益（稀释后）AEMDANGO
| Q4 25 | — | $-0.15 | ||
| Q3 25 | — | $-0.26 | ||
| Q2 25 | — | $-0.15 | ||
| Q1 25 | — | $-0.11 | ||
| Q4 24 | $-10.05 | $-0.26 | ||
| Q3 24 | $-16.11 | $-0.31 | ||
| Q2 24 | — | $-0.35 | ||
| Q1 24 | — | $-4.67 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $4.8M | $41.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $4.3M | $176.3M |
| 总资产 | $6.5M | $269.7M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AEMDANGO
| Q4 25 | — | $41.6M | ||
| Q3 25 | — | $38.8M | ||
| Q2 25 | — | $55.9M | ||
| Q1 25 | — | $44.8M | ||
| Q4 24 | $4.8M | $54.1M | ||
| Q3 24 | $6.9M | $55.0M | ||
| Q2 24 | — | $76.1M | ||
| Q1 24 | — | $78.5M |
总债务AEMDANGO
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $0 | ||
| Q1 24 | — | — |
股东权益AEMDANGO
| Q4 25 | — | $176.3M | ||
| Q3 25 | — | $178.9M | ||
| Q2 25 | — | $183.0M | ||
| Q1 25 | — | $185.9M | ||
| Q4 24 | $4.3M | $186.8M | ||
| Q3 24 | $6.0M | $196.6M | ||
| Q2 24 | — | $205.6M | ||
| Q1 24 | — | $218.7M |
总资产AEMDANGO
| Q4 25 | — | $269.7M | ||
| Q3 25 | — | $265.6M | ||
| Q2 25 | — | $280.1M | ||
| Q1 25 | — | $285.4M | ||
| Q4 24 | $6.5M | $291.6M | ||
| Q3 24 | $8.8M | $293.6M | ||
| Q2 24 | — | $317.7M | ||
| Q1 24 | — | $324.8M |
负债/权益比AEMDANGO
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.00× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-2.0M | $4.7M |
| 自由现金流经营现金流 - 资本支出 | $-2.0M | $4.2M |
| 自由现金流率自由现金流/营收 | -3357.0% | 5.3% |
| 资本支出强度资本支出/营收 | 3.7% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-9.3M |
8季度趋势，按日历期对齐
经营现金流AEMDANGO
| Q4 25 | — | $4.7M | ||
| Q3 25 | — | $-15.9M | ||
| Q2 25 | — | $18.8M | ||
| Q1 25 | — | $-13.2M | ||
| Q4 24 | $-2.0M | $2.5M | ||
| Q3 24 | $-2.2M | $-18.3M | ||
| Q2 24 | — | $5.0M | ||
| Q1 24 | — | $-12.5M |
自由现金流AEMDANGO
| Q4 25 | — | $4.2M | ||
| Q3 25 | — | $-16.6M | ||
| Q2 25 | — | $18.0M | ||
| Q1 25 | — | $-15.0M | ||
| Q4 24 | $-2.0M | $1.7M | ||
| Q3 24 | — | $-19.3M | ||
| Q2 24 | — | $4.4M | ||
| Q1 24 | — | $-13.1M |
自由现金流率AEMDANGO
| Q4 25 | — | 5.3% | ||
| Q3 25 | — | -22.0% | ||
| Q2 25 | — | 22.5% | ||
| Q1 25 | — | -20.8% | ||
| Q4 24 | -3357.0% | 2.3% | ||
| Q3 24 | — | -28.7% | ||
| Q2 24 | — | 6.2% | ||
| Q1 24 | — | -17.5% |
资本支出强度AEMDANGO
| Q4 25 | — | 0.5% | ||
| Q3 25 | — | 1.0% | ||
| Q2 25 | — | 1.0% | ||
| Q1 25 | — | 2.5% | ||
| Q4 24 | 3.7% | 1.1% | ||
| Q3 24 | 0.0% | 1.6% | ||
| Q2 24 | — | 0.8% | ||
| Q1 24 | — | 0.8% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AEMD
暂无分部数据
ANGO
| Med Device | $37.2M | 47% |
| Med Tech | $30.4M | 38% |
| Other | $11.8M | 15% |
